



COQUI RADIOPHARMACEUTICALS

U.S. Nuclear Regulatory Commission  
ATTN: Document Control Desk  
Washington, DC 20555-0001

August 1, 2011

REFERENCE: (a) NRC Regulatory Issue Summary 2011-06, Pre-Application Communication and Voluntary Submittal of Schedule for Future Molybdenum-99 Facility Licensing Actions for NRC Review (July 1, 2011)

Coquí Radiopharmaceuticals Corp. (Coquí) hereby responds to the Nuclear Regulatory Commission (NRC) scheduling information request contained in Reference (a). In the interest of continuing its efforts to develop a high quality licensing submittal for the NRC and in order to ensure that the NRC has the most accurate scheduling information, Coquí has decided that it is best not to provide information on a projected schedule at this time. Coquí will promptly supplement this response as additional information about its plans and schedule becomes certain.

If you have questions or need additional information, please contact me at 787.993.2800 or by email at [cbigles@adioscancer.com](mailto:cbigles@adioscancer.com).

Sincerely,

Carmen I. Bigles  
President and Chief Executive Officer  
Coquí Radiopharmaceuticals Corp.

cc: Mary Jane Ross-Lee  
Ossy Font  
Marcus Voth

Urb. Santa Rosa, 11-25 Carr. 174, Bayamón, Puerto Rico 00959  
Tel. (787) 993-2800, Fax (787) 778-5472

4801  
NRC

Add: M. Voth  
to ERIS

---

Coqui Radiopharmaceutical, Corp.  
P.O. Box 958  
Bayamon, P.R. 00960-0958

U.S. Nuclear Regulatory Commission  
ATT: Document Control Desk  
Washington, DC 20555-0001